Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US11103593B2 · kind B2 · utility
4Cited by
91References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2014 |
| Grant date | Aug 31, 2021 |
| Priority date | — |
| Expiry date | Oct 29, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.